---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-282855"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2026-06-25T20:26:17+00:00"
generated_at: "2026-06-25T20:27:19.198537+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Taysha Gene Therapies prices $200M public offering of 32.5M shares at $6.00/share

## Summary
- Offering of 32,500,001 shares at $6.00/share and 833,333 pre-funded warrants at $5.999.
- Net proceeds ~$187.4M; up to ~$215.6M if underwriters exercise 5M over-allotment option.
- Underwriters: Jefferies, Goldman Sachs, Piper Sandler, Cantor; Baird as lead manager.
- Company expects cash runway into second half of 2028.
- Offering expected to close June 26, 2026; dilution to existing shareholders.

## SEC filing metadata
- accession: 0001193125-26-282855
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2026-06-25T20:26:17+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312526282855/0001193125-26-282855-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312526282855/d121397d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-282855
- JSON: https://secwatch.observer/filing/0001193125-26-282855.json
- Plain text: https://secwatch.observer/filing/0001193125-26-282855.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.